texas oncology more breakthroughs. more victories

Share:

 
 

Community Oncologists Divided on the Value of Biosimilars

Publication: The Center for Biosimilars

At the Community Oncology Alliance Payer Summary, Dr. Lalan Wilfong, medical oncologist with Texas Oncology–Presbyterian Cancer Center Dallas, discussed the upcoming availability of anticancer biosimilars as treatment options. According to Dr. Wilfong, practices are looking forward to the development of biosimilars due to the prospect that prices may fall for cancer therapy.

Read the full story at The Center for Biosimilars.

Related Physicians

Related Cancer Centers